Recent Advances on Small-Molecule Survivin Inhibitors

Author(s): Min Xiao, Wei Li

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 9 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Survivin, a member of the inhibitor of apoptosis proteins family, is highly expressed in most human neoplasms, but its expression is very low or undetectable in terminally differentiated normal tissues. Survivin has been shown to inhibit cancer cell apoptosis and promote cell proliferation. The overexpression of survivin closely correlates with tumor progression and drug resistance. Because of its key role in tumor formation and maintenance, survivin is considered as an ideal target for anticancer treatment. However, the development of small-molecule survivin inhibitors has been challenging due to the requirement to disrupt the protein-protein interactions. Currently only a limited number of survivin inhibitors have been developed in recent years, and most of these inhibitors reduce survivin levels by interacting with other biomolecules instead of directly interacting with survivin protein. Despite these challenges, developing potent and selective small-molecule survivin inhibitors will be important both in basic science to better understand survivin biology and in translational research to develop potentially more effective, broad-spectrum anticancer agents. In this review, the functions of survivin and its role in cancer are summarized. Recent developments, challenges, and future direction of small-molecule survivin inhibitors are also discussed in detail.

Keywords: BIRC5 inhibitor, inhibitor of apoptosis proteins, protein-protein interaction inhibitor, small-molecule anticancer agent, survivin and cancer, survivin inhibitor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 January, 2015
Page: [1136 - 1146]
Pages: 11
DOI: 10.2174/0929867322666150114102146
Price: $65

Article Metrics

PDF: 58
PRC: 1